Neurohumoral fluid regulation in chronic liver disease.
Impaired homeostasis of the blood volume, with increased fluid and sodium retention, is a prevailing element in the deranged systemic and splanchnic haemodynamics in patients with liver disease. In this review, some basic elements of the circulatory changes that take place and of neurohumoral fluid regulation are outlined in order to provide an update of recent investigations on the neuroendocrine compensation of circulatory and volume dysfunction in chronic liver disease. The underlying pathophysiology is a systemic vasodilatation in which newly described potent vasoactive substances such as nitric oxide and vasodilating peptides seem to play an important role. The development of central hypovolaemia and activation of potent vasoconstricting systems such as the renin-angiotensin-aldosterone system and the sympathetic nervous system lead to a hyperdynamic circulation with increased heart rate and cardiac output. Moreover, patients exhibit an autonomic dys- and hyperfunction with vascular hyporeactivity to pressor stimuli. The circulatory dysfunction may be part of a multiorgan failure with disturbed haemodynamics of various vascular beds, including those of the splanchnic system, kidneys, brain and lungs. It is still an enigma why patients with chronic liver disease are at the same time overloaded and functional hypovolaemic with a hyperdynamic, hyporeactive circulation. Further research is needed to find the solution to this apparent haemodynamic conflict concerning the abnormal neurohumoral fluid regulation in chronic liver disease.
Møller
S
S
Department of Clinical Physiology, Hvidovre Hospital, University of Copenhagen, Denmark.
Henriksen
J H
JH
D053607:Adrenomedullin; D001826:Body Fluids; D015740:Calcitonin Gene-Related Peptide / Q000494:pharmacology*; D006439:Hemodynamics; D006706:Homeostasis / Q000187:drug effects*; D006801:Humans; D007668:Kidney / Q000503:physiopathology; D008107:Liver Diseases / Q000503:physiopathology*; D009569:Nitric Oxide / Q000494:pharmacology*; D010455:Peptides / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*
D010455:Peptides; D014665:Vasodilator Agents; D053607:Adrenomedullin; D009569:Nitric Oxide; D015740:Calcitonin Gene-Related Peptide